Biomea Fusion (BMEA) Receivables (2020 - 2021)
Biomea Fusion (BMEA) posted Receivables of $36000.0 for Q1 2021, up 50.0% sequentially from $24000.0 in Q4 2020.
Biomea Fusion (BMEA) Receivables (2020 - 2021) Analysis & Trends
Biomea Fusion has reported Receivables for 2 years, with the latest figure at $36000.0 in Q1 2021.
- Quarterly Receivables changed N/A year-over-year to $36000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $36000.0 (changed N/A YoY) and the FY2020 annual result came in at $24000.0, changed N/A from the prior year.
- Receivables advanced to $36000.0 in Q1 2021 per BMEA's latest filing, from $24000.0 in the prior quarter.
- Over five years, Receivables peaked at $36000.0 in Q1 2021 and troughed at $24000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 36,000.00 |
| Dec 31, 2020 | 24,000.00 |